U.S. markets open in 3 hours 35 minutes
  • S&P Futures

    4,162.75
    -13.00 (-0.31%)
     
  • Dow Futures

    34,135.00
    -71.00 (-0.21%)
     
  • Nasdaq Futures

    12,738.75
    -38.00 (-0.30%)
     
  • Russell 2000 Futures

    1,969.50
    -9.80 (-0.50%)
     
  • Crude Oil

    78.07
    +0.93 (+1.21%)
     
  • Gold

    1,893.80
    +9.00 (+0.48%)
     
  • Silver

    22.47
    +0.29 (+1.32%)
     
  • EUR/USD

    1.0749
    +0.0018 (+0.17%)
     
  • 10-Yr Bond

    3.6740
    0.0000 (0.00%)
     
  • Vix

    18.81
    -0.62 (-3.19%)
     
  • GBP/USD

    1.2091
    +0.0039 (+0.32%)
     
  • USD/JPY

    130.8570
    -0.2150 (-0.16%)
     
  • BTC-USD

    23,173.25
    +165.27 (+0.72%)
     
  • CMC Crypto 200

    534.43
    +8.47 (+1.61%)
     
  • FTSE 100

    7,925.86
    +61.15 (+0.78%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

MyoKardia Reports Third Quarter 2020 Financial Results

Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020

BRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020.

Recent Clinical Program Highlights

Mavacamten for Hypertrophic Cardiomyopathy (HCM)

  • EXPLORER-HCM Data Presented at the European Society of Cardiology 2020 Virtual Congress and Published in The Lancet: Results from MyoKardia’s Phase 3 clinical study of mavacamten for the potential treatment of symptomatic, obstructive HCM demonstrated statistically significant improvements in patient symptoms and cardiac function, as well as reductions in left ventricular outflow tract (LVOT) obstruction. In addition to meeting the primary and all secondary endpoints, mavacamten showed reductions in biomarkers of cardiac wall stress and myocardial injury and was well tolerated, with a safety profile similar to placebo. The benefits observed were consistent across multiple prespecified subgroups.

Danicamtiv (formerly MYK-491) for Dilated Cardiomyopathy (DCM)

  • Initiated Phase 2 Clinical Trial of Danicamtiv in Genetic DCM: Danicamtiv binds directly to and activates myosin, the heart’s motor protein, to boost the power of each contraction without impacting the ability of the heart to relax and fill with oxygenated blood. MyoKardia’s Phase 2 study of danicamtiv is enrolling patients with DCM with documented genetic variants of MYH7 or titin. Pathogenic variants in single genes encoding proteins of the sarcomere have been associated with the contractile dysfunction underlying approximately 20-30 percent of dilated cardiomyopathies.

Recent Corporate Highlights

  • Entered into Strategic Partnership with LianBio to Develop and Commercialize Mavacamten in China: The partnership will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow, in keeping with MyoKardia’s development strategy.

  • Bristol-Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash: Bristol-Myers Squibb (BMS) and MyoKardia announced a definitive merger agreement under which BMS will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction is expected to close during the fourth quarter of 2020.

Third Quarter 2020 Financial Results

  • Cash Position: Cash, cash equivalents and investments as of September 30, 2020 were $895.9 million, compared to $430.3 million as of December 31, 2019. The quarter end cash receipts include $40.0 million from LianBio related to the strategic partnership to develop and commercialize mavacamten in greater China.

  • R&D Expenses: Research and development expenses were $59.1 million in the third quarter of 2020, up from $47.4 million for the same period in 2019. The increase in R&D expenses was primarily driven by the payment of approximately $10.0 million to Fulcrum Therapeutics, as well as increases in personnel, facility and information technology expenses, offset by reductions in clinical expenses due to completion of our EXPLORER clinical trial.

  • G&A Expenses: General and administrative expenses were $26.3 million for the third quarter of 2020, compared to $17.7 million for same period in 2019. The increase in G&A expense was primarily driven by increases in personnel and professional fees.

  • Net Loss: Net loss was $84.7 million ($1.60 loss per share) for the third quarter of 2020, compared to a net loss of $141.8 million ($3.07 loss per share) for the third quarter of 2019.

About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Forward-Looking Statements
This press release contains “forward-looking statements” relating to the development and commercialization of MyoKardia’s product candidates, MyoKardia’s collaboration agreement with LianBio, and the pending acquisition of MyoKardia by Bristol Myers Squibb. Such forward-looking statements are generally identified by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks are (i) the development and commercialization of MyoKardia’s product candidates may be delayed or halted for a variety of reasons, (ii) MyoKardia may not realize the anticipated benefits of its collaboration with LianBio, (iii) there can be no guarantee that the acquisition of MyoKardia by Bristol Myers Squibb will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized, (iv) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger agreement and (v) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. Forward-looking statements in this report should be evaluated together with the many uncertainties that affect MyoKardia’s business, particularly those identified in the risk factors in MyoKardia’s most recent Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports filed on Form 10-Q with the SEC, as well as other documents that may be filed by MyoKardia from time to time with the SEC. Except to the extent required by applicable law, MyoKardia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made.

Additional Information about the Proposed Transaction and Where to Find It
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Bristol-Myers Squibb and its acquisition subsidiary filed with the SEC upon commencement of the tender offer. Bristol-Myers Squibb and its acquisition subsidiary have filed a tender offer statement on Schedule TO with the SEC, and MyoKardia has filed a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY MYOKARDIA’S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement were mailed to MyoKardia’s stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement is also available to all stockholders of MyoKardia by accessing www.myokardia.com or by contacting MyoKardia’s Investor Relations contact at ir@myokardia.com. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) are available at no charge on the SEC’s website: www.sec.gov.

MYOKARDIA’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.

Contacts
Michelle Corral
Executive Director, Corporate Communications and Investor Relations
MyoKardia, Inc.
650-351-4690
ir@myokardia.com

Hannah Deresiewicz (investors)
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Julie Normant (media)
W2O
628-213-3754
jnormart@w2ogroup.com

MYOKARDIA, INC.

Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)

September 30,
2020

December 31,
2019

Assets

Current assets

Cash and cash equivalents

$

675,541

$

101,436

Short-term investments

220,338

314,691

Consideration due from related party

35,000

Prepaid expenses and other current assets

12,865

7,709

Total current assets

943,744

423,836

Property and equipment, net

19,982

15,743

Operating lease right-of-use assets

50,433

417

Long-term investments

14,153

Related party warrant derivative asset

18,765

Restricted cash and other

2,737

1,945

Total assets

$

1,035,661

$

456,094

Liabilities and stockholders’ equity

Current liabilities

Accounts payable

$

4,554

$

6,237

Accrued liabilities

40,043

41,292

Operating lease liabilities - current

7,891

383

Total current liabilities

52,488

47,912

Operating lease liability

43,717

Related party liability

93,765

Other long-term liabilities

713

1,908

Total liabilities

190,683

49,820

Commitments and contingencies

Stockholders’ equity

Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding

Common stock, $0.0001 par value, 150,000,000 shares authorized at September 30, 2020 and December 31, 2019; 53,308,689 and 46,379,073 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

5

5

Additional paid-in capital

1,541,679

884,486

Accumulated other comprehensive income

257

549

Accumulated deficit

(696,963

)

(478,766

)

Total stockholders’ equity

844,978

406,274

Total liabilities and stockholders’ equity

$

1,035,661

$

456,094

MYOKARDIA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2020

2019

2020

2019

Operating expenses:

Research and development

$

59,074

$

47,372

$

155,286

$

101,270

Selling, general and administrative

26,329

17,746

66,482

45,153

Repurchase of royalty rights

80,000

80,000

Total operating expenses

85,403

145,118

221,768

226,423

Loss from operations

(85,403

)

(145,118

)

(221,768

)

(226,423

)

Interest and other income, net

668

3,332

3,592

8,775

Loss before income taxes

(84,735

)

(141,786

)

(218,176

)

(217,648

)

Income tax expense (benefit)

9

16

21

(202

)

Net loss

(84,744

)

(141,802

)

(218,197

)

(217,446

)

Other comprehensive (loss) income

(495

)

(44

)

(292

)

520

Comprehensive loss

$

(85,239

)

$

(141,846

)

$

(218,489

)

$

(216,926

)

Net loss per share, basic and diluted

$

(1.60

)

$

(3.07

)

$

(4.38

)

$

(4.91

)

Weighted average number of shares used to compute net loss per share, basic and diluted

53,101,453

46,133,068

49,860,879

44,255,657